Ipca Labs - On Course To Revive Earnings Growth: Motilal Oswal

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.We recently met the management of Ipca Laboratories Ltd. to understand its business outlook in detail:The domestic formulation segment continues on its robust growth path, led by market share gain, favorable price hikes, addition of medical representatives, and its increased presence particularly in the cardiology segment.Ipca Labs' exports opportunity is expected to improve with increased product launches in the UK, new launches and market share gain in Russia, and industry outperformance in Africa branded generics market.After 18% YoY decline in earnings in FY22, we expect 11% earnings compound annual growth rate over FY22- 24, led by 13%/8%/8% sales CAGR in domestic formulation, exports formulations, and active pharma ingredient, respectively..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Ipca Labs - On Course To Revive Earnings Growth: Motilal Oswal

Ipca Labs - On Course To Revive Earnings Growth: Motilal Oswal

Choose a plan